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ABSTRACT 
The macrophage is a type of phagocytic cell, which is a type of cell those are responsible for detecting, engulfing and destroying 
pathogens and apoptotic cells. Macrophages are produced through the differentiation of monocytes, which turn into macrophages 
when they leave the blood. Macrophages also play a role in alerting the immune system to the presence of invaders. Macrophage 
lineage cells present a remarkably versatile array of functional specializations across vertebrates. As resident cells in virtually all 
tissues, macrophages aid in maintaining homeostatic environments, and upon infection, are typically one of the first cell types to 
encounter intruding pathogens, where they orchestrate appropriate immune responses. Another function of macrophages is to alert 
the immune system to microbial invasion. After ingesting a microbe, a macrophage presents a protein on its cell surface called an 
antigen, which signals the presence of the antigen to a corresponding T helper cell. Moreover macrophages might be a successful 
targeting site for targeted drug delivery approaches.  
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INTRODUCTION 
A type of cell derived fromthat ingests (takes in) foreign 
material.Is a kind of swallowing cell, which means it 
functions by literally swallowing up other particles or 
smaller cells Taken from Greek Words (Greek: big 
eaters, from makros "large" + phagein "eat"; abbr. MΦ). 
Human macrophages are about 21 micrometres 
(0.00083 in) in diameter. Monocytes and macrophages 
are phagocytes, acting in both non-specific defense (and 
innate immunity) as well as to help initiate specific 
defence mechanisms (or adaptive immunity) of 
vertebrate animals. They move by action of Amoeboid 
movement.Life time depends on the type of tissue, 
viability ranges between 6 and 16 days. Macrophage 
lineage cells present a remarkably versatile array of 
functional specializations across vertebrates. As resident 
cells in virtually all tissues, macrophages aid in 
maintaining homeostatic environments, and upon 
infection, are typically one of the first cell types to 
encounter intruding pathogens, where they orchestrate 
appropriate immune responses
1
. Macrophages were first 
identified by Elie Metchnikoff as phagocytic cells which 
helped to eliminate pathogens in both invertebrates and 
vertebrates 
2
. In 1905, his research findings suggested 
that macrophages from infected animals had elevated 
ability of killing bacteria, thereby proposing the basis of 
the concept of macrophage activation 
1
.Our 
understanding of macrophage biology has greatly 
expanded since the first description of starfish larvae 
phagocytes in 1882 by Élie Metchnikoff, who was later 
awarded the Nobel Prize for his contribution to cellular 
immunity in 1908 
3
.  
Much of our understanding of macrophage biology 
comes from research in mammalian models, where 
distinct macrophage subsets of have been characterized, 
including classically activated cells by interferons (IFN) 
and tumor necrosis factor alpha (TNFα) (M1); 
alternatively activated cells by IL-4 and IL-13 (M2a); 
 Verma et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2017; 7(6):91-103                       
ISSN: 2250-1177                                                                              [92]                                                                            CODEN (USA): JDDTAO 
macrophages activated by immune complexes or 
apoptotic cells (M2b); and regulatory macrophages, 
deactivated by IL-10, TGF-β, or glucocorticoids (M2c), 
which culminate in the various effector subtypes, 
broadly described as having a “kill” or “heal” response 
(reviewed in)
4
. Recent transcriptomic and proteomic 
analyses of macrophage populations derived by these 
distinct stimuli have underlined the vast complexities of 
these mechanisms at the molecular level, controlling the 
various physiological responses of macrophages
5
.  
In teleosts, the best characterized macrophage phenotype 
is that comparable to the M1 activation state, which 
serves a critical role in host protection. These cells may 
rapidly kill pathogens by engulfment and production of 
toxic reactive intermediates, phagolysosomal 
acidification, and restriction of nutrient availability 
6, 7
. 
Furthermore, M1 macrophages are robust factories of 
cytokines, chemokines, and lipid mediators, which act to 
potentiate and fine-tune the inflammatory and adaptive 
immune responses. More recently, efforts to characterize 
alternative activation states of teleost macrophages are 
focusing on the biology of fish IL4 and IL13 
homologues (IL4/13A and IL4/13B) and arginase 
activity, implying a conserved M2a phenotype 
7
. Similar 
deactivating roles of glucocorticoids (GC), immune 
complexes, IL-10, and TGF-β have been demonstrated 
in teleosts, suggesting conserved functions of these 
ligands in deactivating or aiding in the tissue repair 
8, 9
. 
Characterization of the regulatory mechanisms 
responsible for shaping macrophage polarity is a unique 
challenge in teleosts, as whole-genome duplication and 
gene-specific duplication events, combined with 
disparate evolutionary pressures, have endowed distinct 
teleosts with multiple gene copies, the product of some 
of which may have adopted respectively divergent roles 
10, 11
.  
Although several attempts have been made to classify 
macrophages, the most successful definition is the 
mononuclear phagocytic system (MPS), which 
encompasses these highly phagocytic cells and their 
bone marrow (BM) progenitors. In the MPS schema, 
adult macrophages are defined as end cells of the 
mononuclear phagocytic lineage with tissue 
macrophages deriving from circulating monocytes that 
originate in the BM. However, this definition is 
inadequate as macrophages have several origins during 
ontogeny and each of these different lineages persist into 
adulthood where they display great diversity
12, 13
.  
Other classifications have included binary classifications 
that refer to inflammatory status. These include the 
activated Macrophages (AM) and alternatively activated 
Macrophages (AAM) or M1 or M2 defined by responses 
to the cytokines IFNγ and activation of TLRs and 
IL4/IL13 respectively. While this is a useful heuristic 
that may reflect extreme states such as in AMs in THI 
mediated immune responses or AAM in parasitic 
infections .it cannot represent the complex in vivo milieu 
for most macrophage types where numerous cytokines 
and growth factors interact to define the final 
differentiated state of macrophages. Indeed 
transcriptional profiling of resident macrophages by the 
“Immunological Genome Project” finds that these 
populations show great transcriptional diversity with 
minimal overlap suggesting many unique classes. 
Macrophages have roles in almost every aspect of an 
organism’s biology ranging from development, 
homeostasis, to repair through to immune responses to 
pathogens
14, 15
. Resident macrophages regulate tissue 
homeostasis by acting as sentinels and responding to 
changes in physiology as well as challenges from 
outside. During these homeostatic adaptations, 
macrophages of different phenotypes can also be 
recruited from the monocyte reservoirs of blood, spleen 
and bone marrow, and perhaps, from resident tissue 
progenitors or through local proliferation. Unfortunately, 
in many cases, these homeostatic and reparative 
functions can be subverted by continuous insult, 
resulting in causal association of macrophages with 
disease states, such as fibrosis, obesity and cancer 
(Figure 1). Macrophages, therefore, are an incredibly 
diverse set of cells constantly shifting their functional 
state to new set points in response to changes in tissue 
physiology or environmental challenges. They should 
not even be considered as one cell type but be 
subdivided into different functional subsets with 
acknowledgement to their different origin
16
. 
In addition to IL-4/IL-13, a great number of stimuli, 
such as antibody immune complexes together with 
lipopolysaccharide (LPS) or IL-1, transforming growth 
factor-β (TGF-β), glucocorticoids and IL-10, were found 
to have the ability of alternative activation of 
macrophages
17
. As they shared properties with IL-4/IL-
13-activated macrophages, a new functional state called 
M2-like phenotype was proposed, and it held great 
promise for the research of macrophage activation in a 
dynamic microenvironment (Figure 1). M1 phenotype 
macrophages express numerous pro-inflammatory 
mediators including tumor necrosis factor (TNF)-α, IL-
1, IL-6, reactive nitrogen and oxygen intermediates, 
which have a strong microbicidal and tumoricidal 
activity; while M2 phenotype express molecules 
including resistin-like-α (also known as Fizz1), 
Arginase1 (Arg1), chitinase 3-like 3 (also known as 
Ym1), IL-10 and Mrc1 (also known as CD206), which 
are supposed to be involved in parasite infestation, tissue 
remodeling and tumor progression (immunoregulatory 
functions)
18
. M1 and M2 phenotype macrophages can be 
converted into each other in their specific 
microenvironment, and they are quite different with Th1 
and Th2. Many key transcription factors are involved in 
macrophage polarization , like signal transducer and 
activator of transcription (STATs), interferon-regulatory 
factor (IRFs), nuclear factor (NF)-κB , activator protein 
(AP) , peroxisome proliferator- activated receptor 
(PPAR)-γ and cAMP-responsive element-binding 
protein (CREB) , which interact with each other and 
regulate macrophages to certain phenotype in the various 
inflammatory diseases (Figure 2). Here we briefly 
review the polarization of macrophages and their 
functions in some typical inflammatory diseases
19
.
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Figure 1: Timeline: advances in research of macrophage polarization
 
 
Figure 2: Signal pathways of macrophage polarization. The figure illustrates several mechanisms underlying 
macrophage polarization and shows the feedback regulation between M1 and M2 signal pathways. Those include the 
activation of STAT1 mediated by IFN-γ receptor, increase in IRF5, NF-κB, as well as AP1 expression mediated by Toll-like 
receptor 4 (TLR4), enhanced AP1 expression mediated by cytokine receptor, activation of STAT6 and increased IRF4 
mediated by IL-4 receptor, increased level of PPARγ mediated by fatty acid receptor, and enhanced expression in CREB by 
TLR4. The feedback regulation between M1 and M2 are implemented by STAT1-STAT6, IRF5-IRF4, NF-κB-PPARγ, AP1-
CREB, and AP1-PPARγ, and they play essential roles in the initiation, development, and cessation of inflammatory diseases.
 
From monocyte to macrophage 
The chemicals secreted by damaged cells, mast cells; 
high conc. of LDL; bacterial by products etc. promote 
upregulation of adhesion molecules on the endothelial 
cells (EC). Thus monocyte and lymphocyte 
recruitmentis initiated. Upregulated exposure of 
adhesion molecules, and chemoattractant production and 
release are essential elements of the transfer of 
monocytes to the intima and the concurrent 
differentiation of these cells into macrophages. Thus the 
differentiation of monocytes into macrophages is a 
chemical process.
20  
Phagocytosis (Paracrine) 
Removal of necrotic cell debris from lungs, spleen, 
bone, liver, neural tissue is one very important task of 
macrophages. This is done by fixed macrophages from 
connective tissue –histiocytes & giant cells. 
 liver sinusoids – Kupffer's cells 
  lung – alveolar macrophages / Dust cells 
  lymph nodes – free and fixed macrophages 
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  spleen – sinusoidal lining cells 
 bone marrow – osteoclast/osteoblast 
  serous fluids –pleural and peritoneal macrophages 
 skin – histiocytes, Langerhans's cell 
Adaptive Immunity
 
When a macrophage ingests a pathogen, the pathogen 
becomes trapped in a phagosome, which then fuses with 
a lysosome. Macrophages can digest more than 100 
bacteria before they finally die due to their own 
digestive compounds. After digesting the pathogen, 
macrophage will present the antigen of the pathogen to 
the corresponding helper T cell. The presentation is done 
by integrating it into the cell membrane and displaying it 
attached to an MHC class II molecule, indicating to 
other white blood cells that the macrophage is not a 
pathogen, despite having antigens on its surface.  
Muscle Regulation
20, 21 
This happens in multiple steps .The first wave of 
phagocytic macrophages degrades and engulfs the 
injured muscle fibres and the debris. (During times of 
increased muscle usage) (ED1+)The second wave of 
non-phagocytic macrophages spreads among the muscle 
fibres and releases chemicals which stimulate 
proliferation of muscles. (ED2+) (It is thought that 
macrophages release soluble substances that influence 
the proliferation, differentiation, growth, repair, and 
regeneration of muscle, but at this time the factor that is 
produced to mediate these effects is unknown.  It is 
known that macrophages' involvement in promoting 
tissue repair is not muscle specific; they accumulate in 
numerous tissues during the healing process phase 
following injury.) Suspected factors: Thrombospondin-
1, TGF-alpha. 
 
TYPES OF MACROPHAGES (ON THE BASIS OF 
ACTIVATION MECHANISM) 
 M1 (classically activated macrophages) 
 Pro-inflammatory phenotype (accelerate 
inflammation) 
 Activated by type 2 interferon (IFN-gamma) and 
tumor necrosis factor(alpha) 
 Released by all due to presence of pathogens 
 M2 (alternatively activated macrophages) 
Anti-Inflammatory Phenotype 
 Activated by Interleukin- 4, interferon type -1(IFN-
alpha) 
 Released by CD4+ T cells (helper T cell) 
 
Figure 3: Anti-Inflammatory Phenotype 
Types of macrophages 
Differentiation of monocyte  
(irf= interferon regulatory facots, ppar=Peroxisome 
proliferator-activated receptor)  
 
 
Figure 4: Macrophage Localisation  
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Macrophages in Inflammation 
 
 
 
 
Figure 5: Macrophages in Inflammation  
 
Formation of macrophage  
The blood monocytes are young cells (immature 
macrophage) that already possess migratory, 
chemotactic, pinocytic and phagocytic activities. Under 
migration into tissues, monocytes undergo further 
differentiation (at least one day) to become 
multifunctional tissue macrophages.  
Macrophage Exhibit 3 main functions in body:   
 1. Destroy bacteria by phagocytosis 
 2. Activate other immune function 
 3. Phagocytose apoptotic cells  
Phagocytosis  
Once it leaves blood vessel and migrated to tissue, the 
next job is to EAT the pathogen. This human 
macrophage, like neutrophil, is a professional 
"phagocyte" or eating cell (phago = "eating", cyte = 
"cell"). Furthermore, the pathogen will be digested by 
using enzyme from macrophage, in the end resulting 
antigen and waste material.   
Steps of phagocytosis 
1. A phagosome is formed to ingest the pathogen 
2. Lysosome + phagosome  phagolysosome 
3. Pathogen is digested by using enzymeand toxic (such 
as superoxideanion or nitric oxide) Secreting waste 
material.  
Perform specific immune function
26  
 After digesting a pathogen, present antigen 
(identification) 
 Churn out powerful chemical substances 
(monokines) including enzymes and complement 
proteins. 
 The presentation is done by integrating it into the 
cell membrane, indicating to other 
 White blood cells that the macrophage is not a 
pathogen, despite having antigens on its surface. 
 Antigen presentation results in the production of 
antibodies that attach to the antigens of pathogens, 
making them easier for macrophages to adhere to 
with their cell membrane and phagocytose. 
 Secrete hormones cytokines 
 To attract system immune cells to the site and 
activate cells involved in tissue repair to send 
signaling path to injury site. 
Phagocytose apoptotic cells 
These reduce the potential for an inflammatory response 
by ensuring that the dying cells are cleared before their 
intracellular contents have released.  
 
 
Programmed 
 NO generation 
Non-programmed 
 NO generation 
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Figure 6: Function of Macrophage  
 
Inflammatory macrophages  
present in various exudates (developmental stage and 
not the functional state) Derived exclusively from 
monocytes, thus similar properties .  
Mechanisms:  
 Intake of monocytes from the circulating blood,  
 Local proliferation and  
 Biological turnover 
 Under Normal Steady-State Conditions, The 
Renewal Of Tissue Macrophages Occurs Through 
Local Proliferation Of Progenitor Cells And Not 
Via Monocyte Influx.   
Mechanism of inflammation  
It is"dynamic response of vascularized tissues to injury” 
It is a complex multi-step process of tissue response to 
injury  
Purposes: 
To defend against injurious agentStart healing & repair 
of injured tissue (bring defence forces such as WBC, 
antibodies, more nutrients and healing factors to the site 
of injury) Localizes infection and prevents spread.  
Chemical mediators : 
Chemical substances synthesised or released which 
mediate the changes in inflammation.  
 Histamine by mast cells - vasodilatation. 
 Prostaglandins – Cause pain & fever. 
 Bradykinin - Causes pain.  
Clinical signs of inflammation (due to vascular 
permeability which allows for phagocytic 
chemotaxis) 
 Lewis triple response 
 Flush (redline) : capillary dilatation 
 Flare (red zone) : arteriolar dilatation 
 Weal (edema) : exudation 
 Classic five signs 
 Rubor(redness) 
 Tumor(swelling)  
 Calor(Heat) 
 Dolor (pain) 
 Loss of function  
Macrophages have numerous different functions that 
may be injurious or reparative. Key issues for the future 
to devise a more complete understanding of the range of 
macrophage activities, how to identify macrophage 
“phenotypes” in vivo and how to manipulate 
macrophage function as therapy.  
Biological functions of macrophages
 
Macrophages are involved at all stages of the immune 
response. First, as already outlined, they act as rapid 
protective mechanism which can respond before T cell-
mediated amplification has taken place. Activated 
macrophages play a key role in host defence against 
intracellular parasitic bacteria, pathogenic protozoa, 
fungi and helminths as well as against tumours, 
especially metastasing tumours. After phagocytosis, 
macrophages prevent intracellularly parasitic organisms 
from replication at least by three ways; Intracellular 
environment is unsuitable for microbial reproduction 
due to low pH and lack of nutrients in a phagolysosome 
.The toxic reaction may be activated to against dividing 
organisms. This include ROI, hypochlorite, NO 
myeloperoxidase, neutral proteases and lysosomal 
hydrolases Macrophages may also produce 
microbiostatic effector molecules at a steady-state and 
thus maintain intracellular microorganisms in the non-
replicating state. This latent infection is generally 
observed only in such individuals whose macrophages 
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cannot be sufficiently activated. Generally, macrophages 
represent the second line of defence against different 
agent.  
In addition, macrophages are important killer cells (K 
cells); by means of antibody-dependent cell-mediated 
cytotoxicity (ADCC) they are able to kill or damage 
extracellular targets. They also take part in the initiation 
of T cell activation by processing and presenting 
antigen. Finally they are central effector and regulatory 
cells of the inflammatory response. To fulfil these 
functions, macrophages in their activated state are able 
to produce more than one hundred of different 
substances.  
Role of Macrophages in inflammation 
Inflammation is a process carried out in response to 
either physical or immunological tissue insults. It 
consists of a destructive process to remove the 
inflammatory trigger and damaged tissue, followed by 
repair and replacement
20
. The main actors in the 
destructive phase are neutrophils and macrophages 
Inflammation is signaled by heat, pain, redness, and 
swelling. Inflammatory conditions are named with the 
suffix itis .Macrophages are highly complex cells 
engaged in normal tissue maintenance and turnover 
among their varied functions, they are sentinels against 
infection, both through the use of receptors for common 
molecules carried by pathogens, and through 
opsonization. Macrophages exist in various levels of 
activation, wherein they become more aggressive at 
destroying macromolecules, and sending distress signals 
to recruit other components of the inflammatory 
response. The most aggressively activated macrophages 
are derived from blood monocytes in response to 
inflammatory signals. These are called “infiltrating 
macrophages
21
.   
Names of macrophages according to tissue locations
22 
S. N. Name Location 
1. Connective tissue Histiocyte 
2. Serous cavity Peritoneal Macrophages 
3. Liver  Kupffer cell 
4. Bone Tissue Osteoclast 
5. Lungs Alveolar Macrophages 
(Dust Cell) 
6. Nervous System Microglial cell 
7. Spleen  Sinusoidal Lining Cell 
8. Skin  Langerhans cell 
9. Inflamed Tissue Infiltrating Macrophahge 
 
Tissue macrophages  
Macrophages can be thought of as a dispersed 
homeostatic organ Tissue macrophages constitute a 
distributed mononuclear phagocyte cellular system 
(MPS), contributing to the body’s responses to 
physiologic changes and to infectious challenge; thus, 
the MPS is comparable to the nervous and endocrine 
systems, in that it is adaptable, regulated and able to 
perform trophic as well as defence functions, locally and 
systemically
26
. Local macrophages induce tissue-
specific metabolic responses such as hepatocyte 
biosynthesis of plasma proteins that provide an early 
response to infection in the acute phase reaction, and 
initiate features of systemic inflammation and infection 
such as loss of appetite and tissue catabolism
27
. The dual 
nature of macrophage functions, host protection versus 
tissue injury, is maintained in a fine balance; broadly, 
macrophage phagocytosis, clearance and secretion 
contribute to innate and adaptive defences against 
infection and underpin the process of inflammation, 
while the same processes, but with distinct secreted 
signals, restore tissue homeostasis and promote 
subsequent repair
28
.  
Myeloid cells of the MPS interact with cells of the 
lymphoid system at many levels, recognition of non-self 
or modified self-antigens, initiating cellular and 
antibody immune responses, while executing effector 
functions which, if excessive or perpetuated, bring about 
tissue destruction. Monocyte migration and widespread 
tissue distribution provide portals for microbial 
dissemination, as well as host protection. During 
malignancy, tissue macrophages play an important role 
in promoting the survival, growth and spread of tumour 
cells
29
.  
Tumor-associated macrophages (TAM) 
Tumors engage the immune system from their inception. 
Initially, this mainly involves cells of the innate system 
such as macrophages and mast cells with their 
prevalence dependent on tumor type. However, even 
early on, there is also engagement of cells of the 
acquired system—particularly T cells (Gajewski et al., 
2013). Nevertheless, despite this adaptive response and 
data that suggest better prognosis with CD8+ T cell 
infiltration in some cancers, there is little evidence of 
immune rejection in established tumors, arguing that the 
local tumor microenvironment is immunosuppressive 
(Gajewski et al., 2013). Macrophages are among the 
most abundant normal cells in the tumor 
microenvironment
30
. Substantial evidence indicates that 
macrophages, rather than being tumoricidal as suggested 
after their activation in vitro (Fidler, 1988), adopt a 
protumoral phenotype in vivo both in the primary and 
metastatic sites (Biswas et al., 2013). Indeed in lung 
cancer, macrophages are polarized to a protumoral 
phenotype at the time of tumor initiation (Redente et al., 
2010). These activities include suppression of T cell 
responses (Coussens et al., 2013; Qian and Pollard, 
2010). In addition, macrophages promote many 
important features of tumor progression including 
angiogenesis, tumor cell invasion, motility, and 
intravasation as well as at the metastatic site, stimulation 
of tumor cell extravasation and persistent growth (Qian 
and Pollard, 2010)
30, 31
.  
Tumor-Associated Macrophages in the Primary Tumor 
Promote Malignancy In the primary tumor, 
microenvironment macrophages under the influence of 
IL-4 produced by CD4+ T cells and tumors and WNT7b 
promote tumor cell invasion. This invasion is mediated 
via a paracrine loop involving tumor-synthesized CSF1 
and macrophage-produced EGF that drives migration of 
tumor cells in lock-step with macrophages along 
collagen fibers that act as highways toward blood 
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vessels
31
. This process also requires TGFb that drives an 
epithelial-mesenchymal transition (EMT) in the tumor 
cells that promotes migration and matrix remodeling via 
Cathepsins and matrix adhesion of tumor cells via 
SPARC. This streaming of tumor cells results in their 
pileup on the vessels where macrophages promote their 
intravasation into the circulation through a structure 
named the ‘‘Tumor Microenvironment of Metastasis’’ 
(TMEN). In addition to effect on tumor cell migration 
and invasion, TIE2+ macrophages produce VEGF and 
WNT7b that stimulates angiogenesis in the tumor. Thus, 
there is an additive effect caused by macrophages of 
increased migration of tumor cells toward vessels and 
increased vascular targets that results in a large number 
of circulating tumor cells and thus increased 
malignancy
32
.   
The role of tumor-associated macrophages in human 
skin cancer  
Inflammation is recognized as being important for 
tumorigenesis and was recently proposed as the seventh 
hallmark of cancer 
33
. The inflammatory infiltrate in 
tumors most commonly consists predominantly of 
macrophages, T cells, neutrophils, natural killer (NK) 
cells – but includes other hematopoietic cells 34. Among 
these cells, macrophages are the most numerous cells in 
this tumor infiltrate. Tumor-associated macrophages 
(TAMs) are closely involved in multiple stages of 
carcinogenesis: they contribute to initiation, growth, 
invasion, and metastasis of tumors through production 
of a diverse array of cytokines, growth factors, pro-
angiogenic factors, and matrix metalloproteinases 
35
the 
most common cancer in the United States is non-
melanoma skin cancer with an estimated 1.3 million 
cases each year. The incidence of NMSC is increasing 
worldwide. It is essential to understand macrophage 
phenotypic characteristics in tumours of diverse clinical 
behaviour to understand which factors correlate with 
tumor growth, invasion and metastasis. The two most 
common forms of NMSC are basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC). BCC and 
SCC are ideal tumors to consider in study of TAMs in 
humans as they represent two common epidermal 
neoplasms that behave differently clinically. BCCs only 
grow and invade locally and do not metastasize. In 
contrast, SCCs are more invasive and can metastasize in 
late stages. Sun exposure, specifically UV-B radiation, 
is considered to be one of the most important 
environmental factors involved in initiation of SCC. 
UV-B exposure directly leads to DNA and RNA 
damage through formation of pyrimidine dimers
36
. A 
limited number of studies have examined the role of 
macrophages in skin cancer. In BCC, it has been shown 
recently that the number of TAMs infiltrating the tumor 
directly correlates with depth of tumor invasion and 
microvessel density. In cutaneous SCC, TAMs are 
shown to be a major source of VEGF-C, a critical 
lymphangiogenic factor
37
. Therefore, study of in vivo 
TAMs in SCC and BCC represents a suitable strategy 
for further understanding of cutaneous carcinogenesis. 
TAMs classically exhibit two states of activation known 
as M1 and M2 states. Macrophages are polarized in 
response to Th1 cytokines, LPS and IFN-gamma, into 
an M1 state. On the other hand, in response to Th2 
cytokines, IL-4 and IL-13, macrophages enter an M2 
state. M1 macrophages are inflammatory and produce a 
variety of pro-inflammatory factors such as IL-1β, TNF-
α, and IL-6. In general, M1 macrophages are involved in 
clearance of microorganisms
38
. M2 macrophages on the 
other hand are involved in type 2 inflammation, tissue 
remodelling, angiogenesis, and are believed to promote 
tumor growth. M2 macrophages produce high levels of 
Interleukin-10 (IL-10) and arginase I and express 
numerous scavenger receptors. The classical M1-M2 
paradigm has been recently revealed to represent two 
ends of a spectrum that can also include heterogeneous 
states of activation. It has been shown in multiple 
studies that macrophages can show mixed states of 
activation and there are multiple sub-populations of 
TAMs
39
.  
Epithelial skin cancers, in particular basal and squamous 
cell carcinomas (BCC and SCC), are the most frequent 
types of cancer in humans, and they are diagnosed in 2–
3 million people worldwide every year
40
. Due to the 
increased life expectancy, the enhanced sun exposure, 
and the treatment of organ transplant patients with 
immunosuppressive compounds, the incidence of 
epithelial skin cancer is continuously increasing 
(Griffin et al, 2016). Cutaneous SCCs often develop 
from precursor lesions, of which actinic keratosis (AK) 
is the most frequent one. Thus, it has been estimated that 
65% of cutaneous SCCs arise from AK 
(Criscione et al, 2009)
41,42
. AK develops at multiple 
sites, in particular in sun‐exposed skin, and its treatment 
is important due to the risk of malignant transformation 
(Werner et al, 2013). Importantly, it is generally 
difficult to predict whether an AK lesion will progress to 
SCC, and it is therefore important to identify biomarkers 
that indicate a high risk for malignant progression. This 
requires a thorough understanding of the 
pathomechanisms underlying AK development and 
progression and the identification and functional 
characterization of the involved cell types and 
genes/proteins. Some of them may represent novel 
targets for therapeutic intervention. They include 
proteins that directly affect proliferation, survival and 
migration of keratinocytes and their malignant 
transformation, but also proteins that act on various 
components of the tumor stroma. Among the latter is the 
growth and differentiation factor activin, a member of 
the transforming growth factor β (TGF‐β) family. 
Activins are homo‐ or heterodimers composed of two β 
chains, with activin A (βAβA) being the most abundant 
and best‐characterized variant (Chen et al, 2006)39. The 
activity of activins is inhibited through binding to the 
secreted glycoproteins follistatin or follistatin‐related 
protein in the extracellular environment (Xia & 
Schneyer, 2009). Activins signal via heterotetrameric 
receptor complexes consisting of type I and type II 
receptors, which are transmembrane serine/threonine 
kinases (Chen et al, 2006)
43
.  
We previously showed that activin is strongly 
upregulated in murine and human skin wounds and in 
human BCCs and SCCs (Hubner et al, 1996; 
Antsiferova et al, 2011)
44
. This is functionally 
important, since overexpression of activin in 
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keratinocytes of transgenic mice accelerated the wound 
healing process (Munz et al, 1999), but also promoted 
skin carcinogenesis and malignant progression of 
existing tumors in a murine skin cancer model where 
tumors are induced by a combination of the mutagen 
7,12‐dimethylbenzo(a)anthracene (DMBA) and the 
tumor promoter 12‐O‐tetradecanoylphorbol‐13‐acetate 
(TPA) (Antsiferova et al, 2011)
45,46
. Interestingly, when 
the activin‐overexpressing mice were mated with 
transgenic mice expressing a dominant‐negative activin 
receptor mutant in keratinocytes, tumor development 
was not inhibited, but rather mildly increased. These 
findings demonstrate that activin does not promote 
tumorigenesis via keratinocytes, but rather has a mild 
tumor‐suppressive effect on these cells. By contrast, 
activin obviously potentiates the oncogenic action of 
DMBA/TPA by generation of a pro‐tumorigenic 
microenvironment. The latter involves loss of 
tumor‐suppressive γδ T cells in the epidermis and a 
concomitant increase in cutaneous αβ T cells and 
Langerhans cells (Antsiferova et al, 2011)
44 45
. However, 
it is unknown whether these cells are indeed 
functionally involved in the tumor‐promoting effect of 
activin, and whether activin has additional, and possibly 
even more important cellular targets. In addition, it 
remains to be determined whether activin promotes skin 
tumorigenesis in more physiologically relevant tumor 
models and whether it is required at an early or late 
stage of skin cancer development. Most importantly, the 
molecular targets of activin in the affected cells of the 
tumor microenvironment remain largely unknown
46, 47
.  
Macrophage infiltration and alternative activation 
during wound healing promote mek1-induced skin 
carcinogenesis  
The notion that the local microenvironment is actively 
involved in tumor development has gained wide 
acceptance in recent years. Interactions between cancer 
cells and surrounding nonmalignant cells are crucial 
determinants of cancer development 
47
. It has been 
suggested that the construction of a pre-cancerous niche 
is required for initiated cancer cells to survive and 
evolve into a tumor . This niche is typically shaped by 
resident or recruited stromal cells, bone marrow derived 
cells, and signals or secreted factors (cytokines, 
chemokines, and exosomes) from all these populations 
.We have previously described a mouse model of wound 
induced, inflammation-mediated skin tumorigenesis 
48
. 
In this model nondividing cells in the suprabasal layers 
of the epidermis express constitutively active MEK1 
(InvEE transgenics), resulting in epidermal 
hyperproliferation and a chronic inflammatory skin 
infiltrate. Between 40% and 60% of InvEE transgenics 
develop benign tumors (papillomas and 
keratoacanthomas) at the site of a full-thickness circular 
wound, several days after the wound has healed. In this 
model MEK1 expressing, nondividing cells stimulate 
keratinocytes in the basal layer to divide and form the 
proliferative compartment of the tumour. MEK1 
expressing suprabasal cells recruit an inflammatory 
infiltrate via secretion of pro-inflammatory cytokines 
including IL1a, which in turn induces expression of 
CD26 on stromal fibroblasts 
49
. The presence of an 
immune infiltrate in InvEE skin is essential for wound-
induced tumor formation, as treatment with the broad-
spectrum anti-inflammatory drug dexamethasone 
protects against tumor formation. Depletion of 
circulating gd T cells, but not ab T cells or B cells, 
reduces the incidence of tumors and leads to a reduction 
in the number of skin macrophages. Depletion of skin 
macrophages by treatment of the wound site with 
clodronate liposomes also decreases tumor incidence
50, 
51
. The identification of macrophages as key contributors 
to InvEE tumor formation is consistent with studies in a 
wide variety of other tumor types. Macrophages are 
highly specialized to support established neoplastic 
lesions, by promoting immunosuppression, proliferation, 
angiogenesis, and metastasis
52, 53
. Correlations between 
persistent, macrophage mediated chronic inflammation 
and cancer have been noted
54, 55
. However, little is 
known about the role of macrophages in the earliest 
stages of tumor development. Initiating events, such as 
tissue or DNA damage caused by the release of 
cytotoxic factors through inflammatory cells, are 
difficult to identify as they may occur long before overt 
tumor development and in most experimental systems 
the precise site of the tumor cannot be predicted. Our 
model allows the observation of events that ultimately 
lead to tumor formation in a well-defined pre-cancerous 
niche, the wound
56, 57
.  
Macrophage polarization in inflammatory diseases  
Macrophages were first identified by Elie Metchnikoff 
as phagocytic cells which helped to liminate pathogens 
in both invertebrates and vertebrates. In 1905, his 
research findings suggested that macrophages from 
infected animals had elevated ability of killing bacteria, 
thereby proposing the basis of the concept of 
macrophage activation
59, 60
. After six decades of efforts, 
the mechanisms with regard to killing bacteria of 
macrophages were gradually elucidated, but there were 
still no definite answers about how macrophages 
became more efficient bacterial k illers. In 1973, North 
and his colleagues found that independent cellular 
factors could also promote resistance of infection 
without involvement of pathogens Almost at the same 
time, David indicated that lymphocytes were the major 
antigen-specific cells responsible for microbicidal 
activation of macrophages
61, 62
 .Soon after that, 
interferon (IFN)-γ, produced by lymphocytes, was 
identified as the firstfactor for interaction between 
macrophages and lymphocytes
59
. It transforms resting 
macrophagesinto active ones which have stronger 
antigen presenting capacity and complement mediated 
phagocytosis,and secrete more pro-inflammatory 
cytokines as well as toxic mediators. As the first type of 
antimicrobialmacrophage activation was recognized, it 
became known as classically activated macrophages 
(CAM, also known as M1). In 1989, when the 
heterogeneity in the helper T-cell compartment was 
subsequently reported, Mosrnann and Coffman 
reviewed the different functions and lymphokines 
secretion between two types of cloned helper T cells 
(Th), and proposed the concept of Th1 and Th2
63, 64
.  
colleagues recognized that interleukin (IL)-4, which was 
mainly produced by Th2 cells, could convert 
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macrophages into a special activation state compared 
with IFN-γ induced activation in which respiratory burst 
was inhibited and major histocompatibility complex 
class II antigens (MHC-II) expression was increased 
65,66
. With the discovery of up-regulation of macrophage 
mannose receptor (MRC1) as a specific marker of IL-
4/IL-13-activated macrophages in 1992, which was 
coupled with the enhanced expression of MHC-II, the 
concept of alternatively activated macrophages (AAM, 
also known as M2) was first proposed . In the following 
years, when the plasticity of macrophages in response to 
different environment was gradually studied, Mosser 
and Edwards reviewed the full spectrum of macrophage 
activation and pointed out that M1 and M2 were two 
terminals of the spectrum 
67,68
.  
Atherosclerosis and cardiovascular diseases  
Atherosclerosis is a common type of degenerative 
disease of the vessel wall characterized by the 
accumulation of apolipoprotein B-lipoproteins in the 
inner lining of large and medium sized arteries 
69
. It 
underlies the leading cause of death in developed 
countries and is likely soon to attain this status 
worldwide. Monocytes and macrophages play essential 
roles in the development of atherosclerosis. As the 
apolipoprotein B-lipoproteins accumulated, the 
endothelial cells become dysfunction and secrete a sum 
of chemokines, which interact with receptors on the 
circulating monocytes and promote them into the vessel 
wall. Those monocytes then transform into macrophages 
and take up cholesterol to give rise to a structure called 
atherosclerotic plaque. As diseases develop, 
atherosclerotic plaque can grow larger, even become 
vulnerable and rupture, potentially resulting in a heart 
attack, stroke and even sudden cardiac death 
70
. The fact 
that prevention of monocyte recruitment by blocking 
chemokines or their receptors could inhibit or slow 
down atherogenesis in mouse model of atherosclerosis, 
might provide strong support for the essential role of 
macrophages in the development of atherosclerosis 
65
.In 
patients with unstable angina and myocardial infarction, 
the pro-inflammatory cytokines secreted by M1 
phenotype macrophages were elevated, such as IL-6, 
with high levels predicating a poor outcome
71
. An in 
vitro study indicated that M1 phenotype macrophages 
could also induce smooth muscle cell proliferation and 
release of vaso active molecules including NO, 
endothelins as well as eicosanoids, and they were 
important consequences for lipoprotein oxidation and 
cytotoxicity. Early atherosclerotic plaques were 
infiltrated by M2 phenotype macrophages, however, 
along with the progression of the plaques, M1 
phenotype macrophages gradually increased and 
occupied a major position, there by more likely leading 
to an acute a the thrombotic vascular accident
72
.  
Obesity and insulin resistance  
Obesity and its attendant metabolic disorder challenge 
the public health of modern society worldwide. Nearly 
75% adults in America are overweight, and more than 
one-third of them are obese. Furthermore, the persistent 
increase in obesity, especially in children, will halt or 
even decrease the life expectancy of America within the 
first half of this century 
73, 74
. As a disease with 
metabolic disturbance, obesity could lead to insulin 
resistance, glucose intolerance dyslipidemia as well as 
hypertension. In addition, recent studies had uncovered 
that obesity was involved in cancers, hepatic and renal 
failure, thrombotic disease, and many infectious 
diseases 
75
. Those findings suggest that obesity should 
pay more attentions than ever before. Substantial 
evidences demonstrate that obesity is a chronic low-
grade inflammatory disease. An important initiator of 
the inflammatory reaction to obesity is adipose tissue, 
which is consisting of adipocytes, preadipocytes, 
endothelial cells and immune cells (e.g., macrophages 
and lymphocytes). In obesity, adipocytes can release 
pro-inflammatory mediators, such as CC chemokine 
ligand (CCL)-2, TNF-α, free fatty acids (FFAs), instead 
of leptin and a diponectin, which promote insulin 
sensitivity in normal state
76, 77
.Those pro-inflammatory 
mediators induce the recruitment and activation of 
adipose tissue macrophage (ATM). The activated ATM 
secrets pro-inflammatory cytokines and forms the 
inflammatory circuit which blocks the insulin action of a 
dipocytes and leads to insulin resistance 
78, 79
.   
Tumor   
It is widely accepted that smouldering inflammation is 
an essential cause of many cancers, and has been 
suggested as the 7th hallmark of cancer 80. Similar to 
other chronic inflammation, cancer-related inflammation 
is also mediated by inflammatory mediators 
(chemokines, cytokines, and prostaglandins) and 
inflammatory cells, constituting a microenvironment for 
the initiation, growth and metastasis ofcancers
81
. Tumor-
associated macrophages (TAM), the major component 
of those inflammatory cells infiltrated in cancer, play 
critical roles in the formation of cancer. In the stage of 
tumor initiation, TAM releases a large amount of 
inflammatory mediators to create an inflammatory 
environment and promote tumor growth. When tumors 
progress to malignancy, TAM contributes to the 
angiogenesis, invasion, metastasis of tumors, and 
decreases the anti-tumor immunity. As tumors become 
metastatic, TAM infiltrates the target tissues and makes 
beds for the arrival of tumor cells. In addition, some 
TAM even changes its phenotype to help extravasation, 
survival, and subsequent growth of tumor cells 
82
. It has 
been demonstrated that there is a strong link between 
poor prognosis and increased TAM in thyroid, lung, and 
hepatocellular tumors. A recent experiment showed that 
an increased number of TAM was strongly associated 
with a shortened survival in classical Hodgkin’s 
lymphoma patients. Therefore, the population of TAM 
could be a biomarker for the risk stratification in tumors 
83
.  
Asthma 
Asthma is a chronic inflammatory disease which is 
wide-spread in both developing and developed 
countries. Disorder in the regulation of phenotypes of 
pulmonary macrophages contributes to the pathogenesis 
of asthma. It is widely accepted that M2 phenotype 
macrophages take a leading role in asthma, which they 
are beneficial for tissue repairing and restoration of 
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homeostasis in the microenvironment of lung tissue. 
However, excessive M2 macrophages may increase cell 
recruitment and mucus secretion, and result in airway 
hyper-responsiveness
84, 85
. Moreira et al transferred M2 
phenotype macrophages into the lungs of fungus-
induced asthmatic mice, then, both the inflammatory 
response and collagen deposition were enhanced, in turn 
accelerating the pathophysiological process of asthma 
86
. 
With a boom in research of macrophage polarization, 
growing evidences support that M1 phenotype 
macrophages contribute to the development of asthma. 
In severe forms of asthma, especially in patients 
resistant to glucocorticoid therapy, macrophages are 
shown to become an M1 phenotype, which produces a 
great amount of pro-inflammatory mediators, including 
TNF-α, IL-1β, NO, exacerbates the lung injury and 
accelerate the airway remodeling For instance, NO 
produced by M1 phenotype leads to oxidative DNA 
damage and inflammation, enhances mucus production, 
and amplifies the lung injury in murine model of 
allergen-induced airway disease 
87
. 
CONCLUSIONS 
Macrophages have numerous different functions that 
may be injurious or reparative. Key issues for the future 
to devise a more complete understanding of the range of 
macrophage activities. In this review , we include all the  
that activin overexpression is an early event in murine 
and human skin carcinogenesis and that increased levels 
of activin strongly promote formation of skin tumors 
induced by the human papillomavirus 8 (HPV8). We 
provide functional evidence for a crucial role of 
macrophages in the pro‐tumorigenic effect of activin. 
Finally, we provide the first genome‐wide RNA 
profiling data of macrophages isolated from 
pre‐tumorigenic lesions, which identified novel activin 
target genes and revealed that activin induces a 
pro‐tumorigenic macrophage phenotype.   
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